Q-omics provides the consensus-scored UVRAG profile across patient tissues and cancer cell-line models. UVRAG expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, UVRAG is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, UVRAG protein abundance shows 21,515 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, HNSC, and LSCC as cancer lineages where UVRAG shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for UVRAG — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes UVRAG survival associations across molecular data types. UVRAG RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible UVRAG RNA expression–survival associations across cancer types. High UVRAG expression shows unfavorable associations in ACC and UCEC, but favorable associations in KIRC, UCS, HNSC and BRCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for UVRAG RNA expression.
This table summarizes UVRAG tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for UVRAG. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. UVRAG shows lower tumor expression in THCA, LUAD and BRCA and higher tumor expression in HNSC, KIRC and LIHC. The HNSC box plot shows higher UVRAG RNA expression in tumor versus normal tissue (log2 FC = +0.911, t-test p < 0.001).
This table shows molecular features associated with UVRAG in patient tissues and cancer cell lines. In patient samples, UVRAG shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, UVRAG RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Lymphoma.
